![Descovy ([emtricitabine + tenofovir alafenamide (TAF)]; Gilead/Japan Tobacco) Drug Overview 2019- Product Image](http://www.researchandmarkets.com/product_images/8219/8219256_500px_jpg/market_research_report.jpg)
Drug Overview
Descovy ([emtricitabine + tenofovir alafenamide (TAF)]; Gilead/Japan Tobacco) is a fixed-dose combination of two of Gilead's nucleos(t)ide reverse transcriptase inhibitors, Emtriva (emtricitabine) and Vemlidy (tenofovir alafenamide [TAF]). The combination is currently approved in the US, Japan, and EU.
Descovy has achieved rapid initial uptake in both the US and EU, driven by its superior renal and bone safety profile compared to its predecessor, Truvada ([emtricitabine + tenofovir disoproxil fumarate (TDF)]; Gilead/Japan Tobacco). With an aging HIV-infected population and increasing scrutiny of the long-term safety of HIV treatments, Descovy’s potential to reduce the real-world incidence of renal dysfunction and bone fractures has allowed it to quickly cannibalize Truvada’s remaining market share within the US and select EU markets. However, within more cost-conservative EU markets, such as the UK, the launch of generic versions of Truvada is a substantial threat to Descovy’s continued growth, as some payers may mandate use of the generic emtricitabine + TDF backbone for patients who are not perceived as being at higher risk of bone or renal disease.
Descovy ([emtricitabine + tenofovir alafenamide (TAF)]; Gilead/Japan Tobacco) is a fixed-dose combination of two of Gilead's nucleos(t)ide reverse transcriptase inhibitors, Emtriva (emtricitabine) and Vemlidy (tenofovir alafenamide [TAF]). The combination is currently approved in the US, Japan, and EU.
Descovy has achieved rapid initial uptake in both the US and EU, driven by its superior renal and bone safety profile compared to its predecessor, Truvada ([emtricitabine + tenofovir disoproxil fumarate (TDF)]; Gilead/Japan Tobacco). With an aging HIV-infected population and increasing scrutiny of the long-term safety of HIV treatments, Descovy’s potential to reduce the real-world incidence of renal dysfunction and bone fractures has allowed it to quickly cannibalize Truvada’s remaining market share within the US and select EU markets. However, within more cost-conservative EU markets, such as the UK, the launch of generic versions of Truvada is a substantial threat to Descovy’s continued growth, as some payers may mandate use of the generic emtricitabine + TDF backbone for patients who are not perceived as being at higher risk of bone or renal disease.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
